Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Published 2011 View Full Article

Authors

Keywords

Journal

ANTI-CANCER DRUGS

Volume 23, Issue 3, Pages 335-341

Publisher

Ovid Technologies (Wolters Kluwer Health)

Online

2011-11-30

DOI

10.1097/cad.0b013e32834e74d6

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

ANTI-CANCER DRUGS

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Create your own webinar